Related Experiment Videos
In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines
1Second Department of Internal Medicine, Okayama University Medical School, Japan.
Background:
The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential.
Materials And Methods:
We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistance cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines.
Results:
IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents.
Conclusion:
These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.
Insights
Antimicrotubule agents show promise for treating small-cell lung cancer (SCLC). Rhizoxin may be particularly effective for patients with refractory or relapsed SCLC, suggesting its utility in salvage therapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Therapeutics
Background:
- Improving treatment outcomes for small-cell lung cancer (SCLC) is crucial.
- Developing novel drugs and overcoming drug resistance in SCLC are essential goals.
Purpose of the Study:
- To evaluate the efficacy of antimicrotubule agents against various human SCLC cell lines.
- To assess the sensitivity of drug-sensitive, intrinsically resistant, and acquired resistant SCLC cell lines to different chemotherapeutic agents.
Main Methods:
- Cytotoxicity of antimicrotubule agents was evaluated against seven human SCLC cell lines.
- Cell lines included drug-sensitive, intrinsically resistant, and acquired resistant (doxorubicin, etoposide, cisplatin) sublines.
- Sensitivity to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, vinblastine, and rhizoxin was assessed.
Main Results:
- Antimicrotubule agents demonstrated lower IC50 values compared to doxorubicin, etoposide, and cisplatin in most SCLC cell lines.
- Acquired resistant sublines (SBC-3/ADM, SBC-3/ETP) showed high resistance to several antimicrotubule agents but retained sensitivity to rhizoxin.
- Cisplatin-resistant subline (SBC-3/CDDP) exhibited no cross-resistance to antimicrotubule agents.
Conclusions:
- Antimicrotubule agents are valuable therapeutic options for small-cell lung cancer.
- Rhizoxin shows potential as a salvage treatment for refractory or relapsed SCLC patients due to its effectiveness against resistant cell lines.